Orion-10 nct03399370
Witryna16 lut 2024 · A total of three Phase 3 studies, i.e., the ORION-9 (NCT03397121), ORION-10 (NCT03399370), and the ORION-11 (NCT03400800) trial, two randomized, double-blind, placebo-controlled, parallel-group, were registered [123,172,173]. This was done to determine the efficacy, safety, and adverse-event profile of inclisiran over 18 … Witryna25 sty 2024 · Ongoing multinational ORION clinical trials are evaluat-ing the long-term safety and ecacy of inclisiran, as well as its use in adults with homozygous familial …
Orion-10 nct03399370
Did you know?
Witryna18 mar 2024 · The objectives of the ORION-10 and ORION-11 trials were to assess the efficacy, safety, and adverse-event profile of inclisiran over a period of 18 months in … Explore a collection of articles and other resources on the Coronavirus (Covid-19… 10. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab i…
Witryna18 mar 2024 · Company; ORION-10 and ORION-11 ClinicalTrials.gov numbers, NCT03399370 and NCT03400800.) ... The ORION-10 trial was conducted in the United States and included adults with atherosclerotic Witryna1 lut 2024 · Inclisiran was also effective in reducing LDL-C levels in patients with ASCVD in the randomized, double-blind, placebo-controlled, phase III ORION-10 trial (NCT03399370) conducted in the USA . Patients eligible for enrolment had elevated LDL-C levels despite receiving maximally tolerated statin therapy with or without additional …
Witryna23 lut 2024 · ORION-8 (NCT03814187), an ongoing open-label extension study of the phase III lipid-lowering trials (ORION-5, ORION-9, ORION-10 and ORION-11), is … WitrynaORION-1: NCT02597127: Phase II; LDL-C lowering: ASCVD, ASCVD RE or HeFH N = 501: June 2024: ORION-2: NCT02963311: Phase II; LDL-C lowering: HoFH N= 4: …
Witryna3 kwi 2024 · Study 1 (ORION-10, NCT03399370) was a multicenter, double-blind, randomized, placebo-controlled 18-month trial in which 1561 patients with ASCVD were randomized 1:1 to receive subcutaneous injections of either LEQVIO 284 mg (n = 781) or placebo (n = 780) on Day 1, Day 90, Day 270, and at Day 450. ...
Witryna20 mar 2024 · More injection-site adverse events occurred with inclisiran than with placebo. (Funded by the Medicines Company; ORION-10 and ORION-11 … nyx eyelash serumWitryna11 kwi 2024 · The goal of this activity is to review the current treatment strategies and recommendations for managing cholesterol in patients at high risk for ASCVD, including the latest clinical trial data for the use of silencing RNA agents against the proprotein convertase subtilisin/kexin type 9 (PSCK9) enzyme. magpul ar folding stockWitrynaPatients who have completed ORION-9, ORION-10, and ORION-11 are eligible for enrollment into ORION-8 (NCT03814187), an ongoing OLE that will monitor … nyx find my shadeWitryna23 gru 2024 · Purpose Patients with polyvascular disease (PVD) are at very high cardiovascular risk and require intensive lipid-lowering therapy. This analysis describes the lipid-lowering efficacy and safety of inclisiran versus placebo in patients with and without PVD. Methods In this post hoc analysis of the ORION-9, ORION-10, and … nyx fill \\u0026 fluff eyebrow pomade pencilWitryna18 mar 2024 · (Funded by the Medicines Company; ORION-10 and ORION-11 ClinicalTrials.gov numbers, NCT03399370 and NCT03400800.). No full-text available Citations (541) ... Hypercholesterolemia is... magpul backpacker pc9Witryna1 lip 2024 · This was a post hoc analysis of patients with heterozygous familial hypercholesterolemia or ASCVD or its risk equivalents randomized 1:1 to 300mg … magpul backup sights setWitryna15 gru 2024 · The ORION-10 trial (NCT03399370) included 1561 patients in North America, and the ORION-11 trial (NCT03400800) included 1617 patients worldwide … nyx ff15